Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control gel Clear all
Recruiting Phase 2 Interventional

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

NCT06852976
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
0.75% MDI-1228_mesylate gel plus Standard of Care, Standard of Care Alone
Drug · Other
Lead sponsor
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 22, 2026, 10:46 AM EDT
Terminated Phase 2 Interventional Results available

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

NCT04493333
View directory record Official record
Conditions
Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions
Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer
Drug · Combination Product
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 22, 2026, 10:46 AM EDT
Active, not recruiting Phase 3 Interventional

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

NCT06239480
View directory record Official record
Conditions
Microcystic Lymphatic Malformation
Interventions
QTORIN 3.9% Rapamycin Anhydrous Gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Irvine, California • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis

NCT00890968
View directory record Official record
Conditions
Hand Dermatoses
Interventions
Triamcinolone Acetonide (TAC) DuraPeel, Placebo DuraPeel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
San Diego, California • Clinton Township, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

NCT02465632
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 22, 2026, 10:46 AM EDT
Recruiting Phase 4 Interventional

Depo-Medrol on Psoas After LLIF

NCT05929755
View directory record Official record
Conditions
Muscle Weakness, Pain, Postoperative, Paresthesia, Pain, Muscle
Interventions
Depo-Medrol, Gel-Flow NT
Drug
Lead sponsor
Hardeep Singh
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 22, 2026, 10:46 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
View directory record Official record
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Not applicable Interventional

Effects of Flourish HEC on Localized Provoked Vulvodynia

NCT05478746
View directory record Official record
Conditions
Vulvodynia, Vestibulodynia, Vulvar Diseases, Vulvar Vestibulitis, Vulvar Pain
Interventions
BioNourish, a component of the Flourish HEC kit, Control - no intervention
Device · Other
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 22, 2026, 10:46 AM EDT
Not listed Phase 2 Interventional

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

NCT02395549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.375% (w/w) MTC896 Gel, 0.75% (w/w) MTC896 Gel, 1.5% (w/w) MTC896 Gel, Vehicle Control Gel
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
16 Years to 65 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK")

NCT03938883
View directory record Official record
Conditions
Ophthalmology, Photorefractive Keratectomy ("PRK"), Laser Assisted Surgery, Refractive Surgery
Interventions
Ocular Bandage Gel (OBG), Bandage Contact Lens (BCL)
Device
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
22 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 22, 2026, 10:46 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis

NCT02434757
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Ronald J. Rapoport, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fall River, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 22, 2026, 10:46 AM EDT
Withdrawn Phase 3 Interventional

Diclofenac Gel in the Treatment of Cervicogenic Headache

NCT05312645
View directory record Official record
Conditions
Cervicogenic Headache
Interventions
Diclofenac 1% Topical, Petroleum Jelly
Drug · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968942
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

NCT02654769
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
22
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 22, 2026, 10:46 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

NCT04807894
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions
Vaginal Cream with Applicator
Drug
Lead sponsor
Jefferson Drapkin
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

NCT02672332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
55
States / cities
Anaheim, California • Encinitas, California • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 22, 2026, 10:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Brain Stimulation and Decision-making

NCT04099056
View directory record Official record
Conditions
Depression
Interventions
Neurostimulation
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

NCT00978042
View directory record Official record
Conditions
Mid-facial Volume Deficit Related to Aging
Interventions
Juvéderm® VOLUMA XC
Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 22, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891
View directory record Official record
Conditions
Cutaneous Common Warts
Interventions
CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
2 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 22, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

NCT06594393
View directory record Official record
Conditions
Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Interventions
TCP-25 gel, Vehicle (placebo)
Drug
Lead sponsor
Xinnate AB
Industry
Eligibility
4 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 10:46 AM EDT
Recruiting Not applicable Interventional

Cold and Compression After Rotator Cuff Repair (RCR)

NCT07516327
View directory record Official record
Conditions
High-grade Partial or Full Thickness Rotator Cuff Tears
Interventions
SOC (Standard of care), Cold and Compression
Other · Device
Lead sponsor
Ochsner Health System
Other
Eligibility
35 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 22, 2026, 10:46 AM EDT
Not listed Phase 2 Interventional

Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain

NCT00801086
View directory record Official record
Conditions
Alopecia
Interventions
7% (w/v) Tempol alcohol-based gel (MTS-01), alcohol-based gel
Drug
Lead sponsor
Mitos Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Tucson, Arizona • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2008 · Synced Oct 22, 2026, 10:46 AM EDT